More tools:Markets·Screener·Research·Chat

Precision BioSciences, Inc. Common Stock (DTIL) Financial Statements

Precision BioSciences, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG008NSBPW2
XNAS · usd
7.38▼ 0.02 (-0.27%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close7.40
Day's Range7.20 – 7.49
52-Week Range3.53 – 9.62
Volume139.6K
Avg Volume260.8K
Share Statistics
Shares Outstanding
Employees68
ExchangeXNAS
Listed2019-03-28
Share count as of August 3, 2026
Loading Income Statement…
Key questions about Precision BioSciences, Inc. Common Stock (DTIL)
What is Precision BioSciences, Inc. Common Stock's Market Cap?
Precision BioSciences, Inc. Common Stock's Market Cap is $203.7M, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's Price / Sales?
Precision BioSciences, Inc. Common Stock's Price / Sales is 4.5×, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's Revenue (TTM)?
Precision BioSciences, Inc. Common Stock's Revenue (TTM) is $45.1M, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's Net Income (TTM)?
Precision BioSciences, Inc. Common Stock's Net Income (TTM) is -$52.7M, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's EBITDA?
Precision BioSciences, Inc. Common Stock's EBITDA is -$35.1M, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's Diluted EPS (TTM)?
Precision BioSciences, Inc. Common Stock's Diluted EPS (TTM) is -1.91, based on as-reported figures from SEC (XBRL) filings.
What is Precision BioSciences, Inc. Common Stock's EBITDA Margin?
Precision BioSciences, Inc. Common Stock's EBITDA Margin is -78.0%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-100.0%+37272.4%+5261.1%-97.7%
Operating expenses
Research and development
General and administrative
Total operating expenses
% of revenue—183.7%63.4%159076.9%
Operating loss
% of revenue—-83.7%36.6%-158976.9%
Other (expense) income:
(Loss) gain from equity method investment
Loss on changes in other fair value adjustments
(Loss) gain on change in fair value of warrant liability
Interest expense
Interest income
Gain (loss) on disposal of assets
Total other expense
Net (loss) income
% of revenue—-170.2%58.9%-167476.9%
Net loss per share
Basic (in USD per shares)
Diluted (in USD per shares)
Weighted-average shares of common stock outstanding
Share-based compensation expense———